Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
Open accessThe DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Abstract
The mammalian (or mechanistic) target of rapamycin (mTOR) pathway has a key role in the regulation of a variety of biological processes pivotal for cellular life, aging, and death. Impaired activity of mTOR complexes (mTORC1/mTORC2), particularly mTORC1 overactivation, has been implicated in a plethora of age‐related disorders, including human renal diseases. Since the discovery of rapamycin (or sirolimus), more than four decades ago, advances in our understanding of how mTOR participates in renal physiological and pathological mechanisms have grown exponentially, due to both preclinical studies in animal models with genetic modification of some mTOR components as well as due to evidence coming from the clinical experience. The main clinical indication of rapamycin is as immunosuppressive therapy for the prevention of allograft rejection, namely, in renal transplantation. However, considering the central participation of mTOR in the pathogenesis of other renal disorders, the use of rapamycin and its analogs meanwhile developed (rapalogues) everolimus and temsirolimus has been viewed as a promising pharmacological strategy. This article critically reviews the use of mTOR inhibitors in renal diseases. Firstly, we briefly overview the mTOR components and signaling as well as the pharmacological armamentarium targeting the mTOR pathway currently available or in the research and development stages. Thereafter, we revisit the mTOR pathway in renal physiology to conclude with the advances, drawbacks, and challenges regarding the use of mTOR inhibitors, in a translational perspective, in four classes of renal diseases: kidney transplantation, polycystic kidney diseases, renal carcinomas, and diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, mTOR has opposite effects on autophagy and cell growth and differentiation — mTOR inhibitors might provide renoprotection by activating autophagy, but they might also inhibit cell growth and therefore hinder kidney repair198,199.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509 · cited 2×
“, serum- and glucocorticoidinduced protein kinase 1, SGK1; protein kinases C, PKC) has been linked with mTORC2 activation, with important consequences on cell survival, cytoskeleton organization, and cycle progression [14, 20, 21].”
BackgroundmTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485 · cited 2×
“Yet, other driver mutations are also involved in the ccRCC development, including those responsible for the constitutive increase in mTOR activation [123, 124].”
BackgroundProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365 · cited 4×
“Yet, there are unique proteins coupled to each complex: mTORC1 is associated with raptor (regulatory-associated protein of mTOR), fundamental for mTORC1 stability and a positive regulator of downstream effectors recruitment and with PRAS40 (proline-rich Akt substrate), a protein which blocks mTORC1 activity; mTORC2 is…”
BackgroundInfluentialA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · cited 3×
“Yet, there are unique proteins coupled to each complex: mTORC1 is associated with raptor (regulatory-associated protein of mTOR), fundamental for mTORC1 stability and a positive regulator of downstream effectors recruitment and with PRAS40 (proline-rich Akt substrate), a protein which blocks mTORC1 activity; mTORC2 is…”
BackgroundReduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810 · cited 1×
“Tacrolimus, in combination with mycophenolate mofetil or mycophenolate sodium (MMF/MPA), showed a remarkable impact on the incidence of acute rejection, which declined to around 5% and 15%, respectively, with a significant improvement in graft and patient survival to over 90% in the first year after transplantation [6…”
BackgroundVÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687 · cited 1×
“: Rapa- (Rapa Nui =Easter Island), -mycin (related to the antifungal properties)), which is a natural antibiotic macrolide firstly isolated from bacterium (Streptomyces hygroscopicus) extracts found on Easter Island soil samples [4].”
BackgroundSellarés, J., de Freitas, D. G., Mengel, M., Reeve, J., Einecke, G., Sis, B., Hidalgo, L. G., Famulski, K., Matas, A., & Halloran, P. F. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03840.x · Cited by 1,590 · cited 1×
“Several factors have been identified to this end, namely, graft quality (older donors, and/or with expanded criteria) and alloantibody-mediated chronic rejection [68].”
BackgroundSabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509 · cited 3×
“Yet, there are unique proteins coupled to each complex: mTORC1 is associated with raptor (regulatory-associated protein of mTOR), fundamental for mTORC1 stability and a positive regulator of downstream effectors recruitment and with PRAS40 (proline-rich Akt substrate), a protein which blocks mTORC1 activity; mTORC2 is…”
BackgroundGuertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415
PKD2 , a Gene for Polycystic Kidney Disease That Encodes an Integral Membrane Protein
Mochizuki, T., Wu, G., Hayashi, T., Xenophontos, S. L., Veldhuisen, B., Saris, J. J., Reynolds, D. M., Cai, Y., Gabow, P. A., Pierides, A., et al. (1996) · Science · doi:10.1126/science.272.5266.1339 · Cited by 1,406
mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
Peterson, T. R., Sengupta, S. S., Harris, T. E., Carmack, A. E., Kang, S. A., Balderas, E., Guertin, D. A., Madden, K. L., Carpenter, A. E., Finck, B. N., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.034 · Cited by 1,229 · cited 1×
“Examples of mTORC1 downstream effectors are the lipin 1/SREBP (sterol regulatory element-binding proteins), the p70S6 kinases (S6K1 and S6K2), and the EIF4EBP1 (eukaryotic translation initiation factor 4E-binding protein 1) [16, 17].”
BackgroundRapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199 · cited 1×
“Hence, mTORC2 is relatively resistant to the effects of rapamycin both in vitro and in vivo, although this phenomenon can be disrupted by chronic treatments [13, 30, 31].”
BackgroundActive-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082 · cited 1×
“In this regard, the mTOR kinase inhibitors appear to have a low side effect profile besides their ability to inhibit both mTORC1 and 2 complexes [109, 121].”
BackgroundAutosomal Dominant Polycystic Kidney Disease
Gabow, P. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290508 · Cited by 974 · cited 4×
“Kidney size can reach significant dimensions as a consequence of the progressive increase in the volume of cysts in about 5% to 8% of the nephrons, leading to a gradual decline of renal function [91].”
BackgroundInfluentialChoueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Kahan, B. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02480-6 · Cited by 913 · cited 1×
“Exciting results were observed when sirolimus was combined with cyclosporine and prednisone, leading to a significant reduction in the incidence of acute rejection when compared to azathioprine or placebo, despite persistent high triglyceride levels [69, 70].”
BackgroundShillingford, J. M., Murcia, N. S., Larson, C. H., Low, S. H., Hedgepeth, R., Brown, N., Flask, C. A., Novick, A. C., Goldfarb, D. A., Kramer-Zucker, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509694103 · Cited by 808 · cited 3×
“Finally, it is important to emphasize that both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin-insensitive) complexes are hyperactivated in PKD [97, 98, 107].”
BackgroundVolume Progression in Polycystic Kidney Disease
Grantham, J. J., Torres, V. E., Chapman, A. B., Guay-Woodford, L. M., Bae, K. T., King, B. F., Wetzel, L. H., Baumgarten, D. A., Kenney, P. J., Harris, P. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054341 · Cited by 807 · cited 1×
“The CRISP study (Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease) showed that renal volume and cysts increase at an exponential rate of about 5% per year and that this increase, as detected by magnetic resonance imaging, is accompanied by progressive deterioration in renal function [92].”
MethodBhaskar, P. T., & Hay, N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.03.020 · Cited by 798 · cited 1×
“mTOR is a member of the phosphatidylinositol 3-kinaserelated kinase (PIKK) family, which is one of the key players of cellular metabolism that is coupled with nutrient availability, energy, and homeostasis [5, 6].”
BackgroundRegulation of mTORC1 by amino acids
Bar-Peled, L., & Sabatini, D. M. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.03.003 · Cited by 773 · cited 1×
“mTORC1 broadly senses nutrients, growth factors, mitogens, and stress signals, thus being generally associated with cell growth by regulating important cellular processes, including the translation of mRNAs into the synthesis of key proteins for proliferation, lipid synthesis, mitochondrial biogenesis, and autophagy […”
BackgroundmTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Dowling, R. J. O., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B. D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y., et al. (2010) · Science · doi:10.1126/science.1187532 · Cited by 726 · cited 1×
“The data suggest that rapamycin impairs mTORC1 activity mainly by preventing the association and phosphorylation of substrates into the kinase complex [33, 34].”
BackgroundActivation of mTORC2 by Association with the Ribosome
Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 654 · cited 1×
“Nevertheless, plasma membrane localization as well as ribosome-binding through insulin-stimulated phosphatidylinositol 3-kinase (PI3K) signaling seem to have a chief role in mTORC2 regulation [18, 19].”
BackgroundPolycystic kidney disease: The complete structure of the PKD1 gene and its protein
The International Polycystic Kidney Disease Consortium (1995) · Cell · doi:10.1016/0092-8674(95)90339-9 · Cited by 625 · cited 2×
“About 85% of ADPKD is caused by mutations in the PKD1 gene which encodes polycystin-1, a large glycosylated integral membrane protein receptor present in the plasma membrane and in the renal tubular epithelium as well as in the bile and pancreatic ducts [93].”
BackgroundEverolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Walz, G., Budde, K., Mannaa, M., Nürnberger, J., Wanner, C., Sommerer, C., Kunzendorf, U., Banas, B., Hörl, W. H., Obermüller, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003491 · Cited by 587 · cited 1×
“It was observed that in treated patients, cysts volume growth rate and renal parenchyma decreased; however, at the end of the study, no eGFR significant difference was found [113].”
BackgroundSirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907419 · Cited by 571 · cited 1×
“, and after 18 months of observation, patients with eGFR> 70mL/min and kidney volume of about 1000mL, rapamycin did not modify the eGFR, nor the total renal volume, compared to the control group, while albuminuria increased in the treated group [111].”
BackgroundRole of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547 · cited 4×
“Briefly, these studies make use of two distinct models to show that mTORC1 overactivation in nondiabetic mice caused a glomerular disease closely resembling DN, while podocytespecific inhibition of mTORC1 activity protected mice from DN development [58, 143].”
BackgroundResultInfluentialmTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44771 · Cited by 538 · cited 2×
“Briefly, these studies make use of two distinct models to show that mTORC1 overactivation in nondiabetic mice caused a glomerular disease closely resembling DN, while podocytespecific inhibition of mTORC1 activity protected mice from DN development [58, 143].”
BackgroundResultTSC2 regulates VEGF through mTOR-dependent and -independent pathways
Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00187-9 · Cited by 528 · cited 18×
“XL388 was significantly more potent in RCC cell death than rapalogues and showed efficacy in 786-0 RCC tumor growth in nude mice.”
BackgroundInfluentialBrook-Carter, P. T., Peral, B., Ward, C. J., Thompson, P., Hughes, J., Maheshwar, M. M., Nellist, M., Gamble, V., Harris, P. C., & Sampson, J. R. (1994) · Nature Genetics · doi:10.1038/ng1294-328 · Cited by 510
Twenty-five years of mTOR: Uncovering the link from nutrients to growth
Sabatini, D. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716173114 · Cited by 501
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. (2016) · Nature · doi:10.1038/nature17963 · Cited by 479
Houde, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A. (2010) · Diabetes · doi:10.2337/db09-1324 · Cited by 456 · cited 1×
“Activation of mTOR complexes 1 and 2 promotes fat deposition in the adipose tissue [138, 139], which is in agreement with the rapamycininduced hyperlipidemia seen clinical practice [140].”
BackgroundGenetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases
Cornec-Le Gall, E., Torres, V. E., & Harris, P. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017050483 · Cited by 406 · cited 1×
“Disease severity is highly variable, displaying distinct phenotypes ranging from manifestations in utero or during infancy (very early onset (VEO) disease) to clinically silent disease well into the second or third decade of life [89, 90].”
BackgroundInsulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway
Zhang, H. H., Huang, J., Düvel, K., Boback, B., Wu, S., Squillace, R. M., Wu, C.-L., & Manning, B. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006189 · Cited by 399 · cited 1×
“Activation of mTOR complexes 1 and 2 promotes fat deposition in the adipose tissue [138, 139], which is in agreement with the rapamycininduced hyperlipidemia seen clinical practice [140].”
BackgroundRapamycin Markedly Slows Disease Progression in a Rat Model of Polycystic Kidney Disease
Tao, Y., Kim, J., Schrier, R. W., & Edelstein, C. L. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080660 · Cited by 391
Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans
Soukas, A. A., Kane, E. A., Carr, C. E., Melo, J. A., & Ruvkun, G. (2009) · Genes & Development · doi:10.1101/gad.1775409 · Cited by 380 · cited 1×
“Activation of mTOR complexes 1 and 2 promotes fat deposition in the adipose tissue [138, 139], which is in agreement with the rapamycininduced hyperlipidemia seen clinical practice [140].”
BackgroundStructure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition
Yip, C. K., Murata, K., Walz, T., Sabatini, D. M., & Kang, S. A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.017 · Cited by 372 · cited 1×
“The data suggest that rapamycin impairs mTORC1 activity mainly by preventing the association and phosphorylation of substrates into the kinase complex [33, 34].”
BackgroundBudde, K., Becker, T., Arns, W., Sommerer, C., Reinke, P., Eisenberger, U., Kramer, S., Fischer, W., Gschaidmeier, H., & Pietruck, F. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62318-5 · Cited by 359
Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 352 · cited 1×
“The prototype molecule in this class is the pyridofuropyrimidine PI-103, even though it was never translated into the clinic mainly because of its rapid in vivometabolism [41, 42].”
BackgroundKenerson, H. L., Aicher, L. D., True, L. D., & Yeung, R. S. W. (2002) · PubMed · Cited by 315
Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells
Belibi, F. A., Reif, G., Wallace, D. P., Yamaguchi, T., Olsen, L., Li, H., Helmkamp, G. M., & Grantham, J. J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00843.x · Cited by 295 · cited 3×
“These pathophysiological changes are mainly due to the overactivation of EGFR, cAMP, and mTOR pathway, leading to great interest in research regarding the inhibition of this signaling pathway in the treatment of this disease [96, 97].”
BackgroundKahan, B. D., Podbielski, J., Napoli, K. L., Katz, S. M., Meier-Kriesche, H.-U., & Van Buren, C. T. (1998) · Transplantation · doi:10.1097/00007890-199810270-00013 · Cited by 288
Why kidneys fail in autosomal dominant polycystic kidney disease
Grantham, J. J., Mulamalla, S., & Swenson-Fields, K. I. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.109 · Cited by 287
Wahl, P. R., Serra, A. L., Le Hir, M., Molle, K. D., Hall, M. N., & Wüthrich, R. P. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi181 · Cited by 287
A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy
Lee, M.-J., Feliers, D., Mariappan, M. M., Sataranatarajan, K., Mahimainathan, L., Musi, N., Foretz, M., Viollet, B., Weinberg, J. M., Choudhury, G. G., et al. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00278.2006 · Cited by 285 · cited 1×
“In conditions of overt diabetes, hyperglycemia further exacerbates mTORC1 activation due to inhibition of AMPK phosphorylation [141].”
BackgroundThe Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease
Lieberthal, W., & Levine, J. S. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008111186 · Cited by 280 · cited 2×
“Renal cell carcinoma (RCC) accounts for 2 to 3% of all adult malignancies and is the most common type of kidney cancer [89].”
BackgroundMTOR inhibitors in cancer therapy
Xie, J., Wang, X., & Proud, C. G. (2016) · F1000Research · doi:10.12688/f1000research.9207.1 · Cited by 266 · cited 5×
“Since mTORC1 and mTORC2 control events intimately related to cell growth and survival, rapalogues have been extensively studied in the oncology field, with several works conducted to analyze the effectiveness of these class of molecules alone and/or in combination with standard chemotherapy in the treatment of several…”
BackgroundInfluentialLebranchu, Y., Thierry, A., Toupance, O., Westeel, P. F., Etienne, I., Thervet, E., Moulin, B., Frouget, T., Le Meur, Y., Glotz, D., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02615.x · Cited by 263 · cited 1×
“4mL/min), with no statistically significant difference regarding receptor and graft survival [74].”
BackgroundLiefeldt, L., Brakemeier, S., Glander, P., Waiser, J., Lachmann, N., Schönemann, C., Zukunft, B., Illigens, P., Schmidt, D., Wu, K., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03961.x · Cited by 244 · cited 1×
“It is unknown whether this effect was drugrelated or due to corticosteroid suspension [78].”
BackgroundMolecular pathogenesis of ADPKD: The polycystin complex gets complex
Ong, A. C. M., & Harris, P. C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00201.x · Cited by 242 · cited 1×
“Both interact to regulate calcium influx [95].”
Laplante, M., & Sabatini, D. M. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a011593 · Cited by 227
AKT2 is essential to maintain podocyte viability and function during chronic kidney disease
Canaud, G., Bienaimé, F., Viau, A., Treins, C., Baron, W., Nguyen, C., Burtin, M., Berissi, S., Giannakakis, K., Muda, A. O., et al. (2013) · Nature Medicine · doi:10.1038/nm.3313 · Cited by 222 · cited 2×
“Furthermore, prevention of mTORC2-Akt2 activation by rapamycin in biopsy tissue from kidney transplant patients was accompanied by increased glomerular apoptosis [64], reinforcing the notion that mTORC2 (along with mTORC1) might contribute to rapamycin-induced proteinuria.”
BackgroundCella, D., Grünwald, V., Nathan, P., Doan, J., Dastani, H., Taylor, F., Bennett, B., DeRosa, M., Berry, S., Broglio, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30125-5 · Cited by 218
Flechner, S. M., Glyda, M., Cockfield, S., Grinyó, J., Legendre, C., Russ, G., Steinberg, S., Wissing, K. M., & Tai, S. S. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03573.x · Cited by 217 · cited 1×
“The exclusion of calcineurin inhibitors was tested in some studies [71], but with disappointing results due to the high number of acute rejection episodes.”
BackgroundThe PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
Cheaib, B., Auguste, A., & Leary, A. (2015) · Chinese Journal of Cancer · doi:10.5732/cjc.014.10289 · Cited by 216 · cited 1×
“Temsirolimus and sirolimus are also associated with pulmonary toxicity, being interstitial lung disease, risk of secondary lymphoma, and reactivation of latent infections rare side effects [39].”
BackgroundAutosomal Dominant Polycystic Kidney Disease
Gabow, P. A. (1990) · The Cystic Kidney · doi:10.1007/978-94-009-0457-6_12 · Cited by 213
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208 · cited 2×
“In fact, mTOR has presented itself as a valid target for the treatment of RCC, and both everolimus and temsirolimus (first generation of mTOR inhibitors) have EMA- and FDA-approved indications for the treatment of RCC particularly in advanced and/or metastatic RCC patients as well as in patients refractory to anti-VEG…”
BackgroundLocalization of mTORC2 activity inside cells
Ebner, M., Sinkovics, B., Szczygieł, M., Ribeiro, D. W., & Yudushkin, I. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201610060 · Cited by 208 · cited 1×
“Nevertheless, plasma membrane localization as well as ribosome-binding through insulin-stimulated phosphatidylinositol 3-kinase (PI3K) signaling seem to have a chief role in mTORC2 regulation [18, 19].”
BackgroundSirolimus Reduces Polycystic Liver Volume in ADPKD Patients
Qian, Q., Du, H., King, B. F., Kumar, S., Dean, P. G., Cosio, F. G., & Torres, V. E. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050626 · Cited by 204 · cited 1×
“Overall, these clinical results were largely disappointing, taking into account the promising effects of mTOR inhibition in PKD animal models and retrospective studies of kidney transplant recipients undergoing immunosuppression with mTOR inhibitors who displayed reduced liver cystic phenotype [115, 116].”
ResultTargeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders
Maiese, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12804 · Cited by 199 · cited 1×
“rheumatoid arthritis, atherosclerosis and a wide spectrum of neurologic disorders where aberrant mTOR pathway activity is consistently observed [22, 27, 28, 32].”
BackgroundInhibition of the Mechanistic Target of Rapamycin (mTOR)–Rapamycin and Beyond
Lamming, D. W. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025924 · Cited by 195 · cited 2×
“Hence, mTORC2 is relatively resistant to the effects of rapamycin both in vitro and in vivo, although this phenomenon can be disrupted by chronic treatments [13, 30, 31].”
BackgroundCho, D. C., Cohen, M. B., Panka, D. J., Collins, M., Ghebremichael, M., Atkins, M. B., Signoretti, S., & Mier, J. W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3022 · Cited by 192 · cited 1×
“The combined protocol showed positive results with enhanced apoptosis and reduction of renal cancer cell proliferation [134].”
BackgroundFan, Q.-W., Cheng, C. K., Nicolaides, T. P., Hackett, C. S., Knight, Z. A., Shokat, K. M., & Weiss, W. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2154 · Cited by 192
Tamburini, J., Green, A. S., Bardet, V., Chapuis, N., Park, S., Willems, L., Uzunov, M., Ifrah, N., Dreyfus, F., Lacombe, C., et al. (2009) · Blood · doi:10.1182/blood-2008-10-184515 · Cited by 190 · cited 1×
“In contrast to the rapamycin analogs, these molecules exert their effects by directly blocking the ATP catalytic site that is integral to both mTOR complexes (see Figure 1), resulting in widespread inhibition of the mTOR signal [36, 44, 45].”
BackgroundWeir, M. R., Mulgaonkar, S., Chan, L., Shidban, H., Waid, T. H., Preston, D., Kalil, R. N., & Pearson, T. C. (2011) · Kidney International · doi:10.1038/ki.2010.492 · Cited by 185 · cited 1×
“Another study following the same line of research found a better eGFR in the sirolimus group compared to the calcineurin inhibitor at one-year posttransplantation, but after two years this difference disappeared [77].”
ResultMacKeigan, J. P., & Krueger, D. A. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov152 · Cited by 183 · cited 2×
“In contrast to the rapamycin analogs, these molecules exert their effects by directly blocking the ATP catalytic site that is integral to both mTOR complexes (see Figure 1), resulting in widespread inhibition of the mTOR signal [36, 44, 45].”
BackgroundA Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Fan, Q., Aksoy, O., Wong, R. A., Ilkhanizadeh, S., Novotny, C. J., Gustafson, W. C., Truong, A. Y.-Q., Cayanan, G., Simonds, E. F., Haas-Kogan, D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.014 · Cited by 180 · cited 1×
“The linker portion between these two molecules—a polyethylene glycol unit—does not disrupt rapamycin binding to FKBP12 or the FRB domain of mTOR, thus leveraging the high selectivity and affinity of rapamycin for mTORC1 and the “deliver” of MLN0128 to the ATP site of mTORC1 [50, 51].”
BackgroundProtor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney
Pearce, L. R., Sommer, E. M., Sakamoto, K., Wullschleger, S., & Alessi, D. R. (2011) · Biochemical Journal · doi:10.1042/bj20102103 · Cited by 179
mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression
Huber, T. B., Walz, G., & Kuehn, E. W. (2010) · Kidney International · doi:10.1038/ki.2010.457 · Cited by 166 · cited 2×
“Regarding interstitial fibrosis, mTOR seems to be able to stimulate fibroblasts proliferation, collagen synthesis, and expression of profibrotic cytokines, such as TGF-β1 and CTGF, which are pivotal players in the tubulointerstitial damage, a crucial feature of DN [142, 151].”
BackgroundSirolimus Therapy to Halt the Progression of ADPKD
Perico, N., Antiga, L., Caroli, A., Ruggenenti, P., Fasolini, G., Cafaro, M., Ondei, P., Rubis, N., Diadei, O., Gherardi, G., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121302 · Cited by 165 · cited 1×
“In another study, higher doses of sirolimus seemed to stabilize cyst volume, comparing to the conventional therapy-treated patients [112].”
ResultInhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice
Sakaguchi, M., Isono, M., Isshiki, K., Sugimoto, T., Koya, D., & Kashiwagi, A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.012 · Cited by 164 · cited 4×
“Podocyte hypertrophy is a pivotal and early step in the glomerular hypertrophy that precedes proteinuria development and irreversible structural changes, culminating in glomerulosclerosis and nephron loss in DN [142].”
BackgroundInfluentialGenetics of Autosomal Recessive Polycystic Kidney Disease and Its Differential Diagnoses
Bergmann, C. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00221 · Cited by 152 · cited 2×
“With advancing clinical course, ARPKD pathophysiological features often resemble the pattern of ADPKD, even though a more severe phenotype is often observed [87].”
BackgroundFlechner, S. M., Goldfarb, D. A., Solez, K., Modlin, C. S., Mastroianni, B., Savas, K., Babineau, D. C., Kurian, S. M., Salomon, D. R., Novick, A. C., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000258586.52777.4c · Cited by 144 · cited 1×
“Only one center achieved satisfactory results when comparing sirolimus and IL2R antibody induction, calcineurin inhibitor-based regimen [72].”
ResultA Dynamic Network Model of mTOR Signaling Reveals TSC-Independent mTORC2 Regulation
Dalle Pezze, P., Sonntag, A. G., Thien, A., Prentzell, M. T., Gödel, M., Fischer, S., Neumann-Haefelin, E., Huber, T. B., Baumeister, R., Shanley, D. P., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2002469 · Cited by 143
Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2
Gaubitz, C., Oliveira, T. M., Prouteau, M., Leitner, A., Karuppasamy, M., Konstantinidou, G., Rispal, D., Eltschinger, S., Robinson, G. C., Thore, S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.031 · Cited by 142 · cited 1×
“Even though the FRB domain is present in both mTORC1/2 complexes, it is only exposed in mTORC1, as Rictor blocks the access of FKBP12rapamycin complex to FRB domain in mTORC2 [25, 29].”
BackgroundLanger, R. M., Hené, R. J., Vitko, S., Christiaans, M. H. L., Junior, H. T. S., Ciechanowski, K., Cassuto, É., Rostaing, L. P. E., Vilatobá, M., Machein, U., et al. (2012) · Transplant International · doi:10.1111/j.1432-2277.2012.01465.x · Cited by 131 · cited 1×
“of acute rejection episodes, without compromising graft function [81].”
BackgroundBudde, K., Lehner, F., Sommerer, C., Reinke, P., Arns, W., Eisenberger, U., Wüthrich, R. P., Mühlfeld, A., Heller, K., Porstner, M., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.12952 · Cited by 130 · cited 1×
“The followup of these patients at five years confirmed that in the first year posttransplant grafts presented better function, but also a higher incidence of acute rejection [76].”
BackgroundPre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma
Zheng, B., Mao, J., Lin, Q., Zhu, H., Gu, D., Pan, X., Fang, Y., & Ji, D. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.012 · Cited by 129 · cited 1×
“Another preclinical study focused on AZD2014, a dual mTORC1/2 inhibitor, showed higher in vitro efficiency in the inhibition of RCC cell survival and growth as well as RCC cell apoptosis when compared with conventional mTORC1 inhibitors (rapamycin), providing evidence for clinical trials using AZD2014 in RCC treatment…”
BackgroundJhanwar‐Uniyal, M., Amin, A. G., Cooper, J., Das, K., Schmidt, M. H., & Murali, R. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2016.12.001 · Cited by 128 · cited 1×
“This phenomenon can seriously compromise the anticancer efficacy as well as the acquisition of chemoresistant phenotypes [22, 23, 25].”
BackgroundPerspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
Chapuis, N., Tamburini, J., Green, A. S., Willems, L., Bardet, V., Park, S., Lacombe, C., Mayeux, P., & Bouscary, D. (2010) · Leukemia · doi:10.1038/leu.2010.170 · Cited by 114 · cited 1×
“In contrast to the rapamycin analogs, these molecules exert their effects by directly blocking the ATP catalytic site that is integral to both mTOR complexes (see Figure 1), resulting in widespread inhibition of the mTOR signal [36, 44, 45].”
BackgroundPereira, M. J., Palming, J., Rizell, M., Aureliano, M., Carvalho, E., Svensson, M. K. E., & Eriksson, J. W. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.01.024 · Cited by 113 · cited 1×
“In this regard, it should be highlighted that rapamycin prevented insulin-mediated suppression of hepatic gluconeogenesis and impaired in vitro basal and insulin-stimulated glucose uptake in adipocytes from human donors [37, 38].”
BackgroundReview of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation
Peddi, V. R., Wiseman, A. C., Chavin, K. D., & Slakey, D. P. (2013) · Transplantation Reviews · doi:10.1016/j.trre.2013.06.001 · Cited by 109
Potential therapeutic effects of mTOR inhibition in atherosclerosis
Kurdi, A., De Meyer, G. R. Y., & Martinet, W. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12820 · Cited by 108 · cited 1×
“rheumatoid arthritis, atherosclerosis and a wide spectrum of neurologic disorders where aberrant mTOR pathway activity is consistently observed [22, 27, 28, 32].”
BackgroundPowles, T. B., Wheater, M. J., Din, O. S., Geldart, T., Boleti, E., Stockdale, A. D., Sundar, S., Robinson, A. J., Ahmed, I., Wimalasingham, A. G., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.08.035 · Cited by 107 · cited 1×
“Nevertheless, a randomized phase II study of AZD2014 versus everolimus in anti-VEGF-refractory metastatic RCC showed inferior progression-free survival (primary endpoint) and overall survival with this TOR-KI, despite favourable toxicity and pharmacokinetic profiles (secondary endpoints) [136].”
BackgroundSignificance and Management of Proteinuria in Kidney Transplant Recipients
Amer, H., & Cosio, F. G. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008091005 · Cited by 107
Ciancio, G., Burke, G. W., Gaynor, J. J., Ruiz, P., Roth, D., Kupin, W. L., Rosen, A. L., & Miller, J. (2006) · Transplantation · doi:10.1097/01.tp.0000203894.53714.27 · Cited by 106 · cited 1×
“In fact, the combined administration of sirolimus with cyclosporine increases its toxicity, implying that a lower dose should be used than with tacrolimus [80].”
BackgroundZafar, I., Ravichandran, K., Belibi, F. A., Doctor, R. B., & Edelstein, C. L. (2010) · Kidney International · doi:10.1038/ki.2010.250 · Cited by 102 · cited 1×
“Finally, it is important to emphasize that both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin-insensitive) complexes are hyperactivated in PKD [97, 98, 107].”
BackgroundmTOR signaling in polycystic kidney disease
Ibraghimov‐Beskrovnaya, O., & Natoli, T. A. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.06.003 · Cited by 97 · cited 2×
“Overall, an abundance of preclinical evidence suggests that mTOR inhibitors effectively slow cyst growth, even though the specific role of mTOR complexes is still poorly understood [104].”
BackgroundDifferentiating mTOR inhibitors in renal cell carcinoma
Pal, S. K., & Quinn, D. I. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.015 · Cited by 95
Dose-Dependent Effects of Sirolimus on mTOR Signaling and Polycystic Kidney Disease
Novalic, Z., van der Wal, A. M., Leonhard, W. N., Koehl, G., Breuning, M. H., Geissler, E. K., de Heer, E., & Peters, D. J. M. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011040340 · Cited by 93
Pereira, M. J., Palming, J., Rizell, M., Aureliano, M., Carvalho, E., Svensson, M. K. E., & Eriksson, J. W. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.10.030 · Cited by 87
Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML
Herschbein, L., & Liesveld, J. L. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.11.006 · Cited by 86 · cited 2×
“Moreover, it was proposed that dual PI3K/mTOR inhibitors suppressed a yet unidentified negative feedback loop mediated by mTORC2, which could partially explain the in vitro resistance and limited efficacy in vivo [25, 43].”
BackgroundVandamme, T., Beyens, M., de Beeck, K. O., Dogan, F., van Koetsveld, P. M., Pauwels, P., Mortier, G. R., Vangestel, C., de Herder, W. W., Camp, G. V., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.25 · Cited by 84 · cited 1×
“Remarkably, mTOR kinase inhibitors (TOR-KIs) were effective antiproliferators in cell models displaying insensitivity to the first-generation of mTOR inhibitors [46, 47].”
BackgroundMetabolic complications with the use of mTOR inhibitors for cancer therapy
Sivendran, S., Agarwal, N., Gartrell, B., Ying, J., Boucher, K. M., Choueiri, T. K., Sonpavde, G., Oh, W. K., & Galsky, M. D. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.04.005 · Cited by 83 · cited 1×
“In this regard, it should be highlighted that rapamycin prevented insulin-mediated suppression of hepatic gluconeogenesis and impaired in vitro basal and insulin-stimulated glucose uptake in adipocytes from human donors [37, 38].”
BackgroundDrug discovery targeting the mTOR pathway
Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 80
Kahan, B. D. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00353-1 · Cited by 75 · cited 1×
“Exciting results were observed when sirolimus was combined with cyclosporine and prednisone, leading to a significant reduction in the incidence of acute rejection when compared to azathioprine or placebo, despite persistent high triglyceride levels [69, 70].”
BackgroundCanaud, G., Knebelmann, B., Harris, P. C., Vrtovsnik, F., Correas, J. ‐., Pallet, N., Heyer, C. M., Letavernier, E., Bienaimé, F., Thervet, E., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03152.x · Cited by 69 · cited 1×
“Another important feature may rely on the fact that mTOR inhibitors used in these trials may exhibit inadequate tissue penetration at clinically tolerable doses [119, 120].”
BackgroundMolecular Pathways and Therapies in Autosomal-Dominant Polycystic Kidney Disease
Saigusa, T., & Bell, P. D. (2015) · Physiology · doi:10.1152/physiol.00032.2014 · Cited by 68 · cited 1×
“Another important feature may rely on the fact that mTOR inhibitors used in these trials may exhibit inadequate tissue penetration at clinically tolerable doses [119, 120].”
BackgroundRenken, C., Fischer, D.-C., Kundt, G., Gretz, N., & Haffner, D. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq384 · Cited by 67 · cited 1×
“Nevertheless, a lack of efficacy was observed in the PCK rat model of ARPKD, Han:SPRD female rats, and early-stage nephronophthisis pcy mice [97, 101, 105].”
BackgroundZheleznova, N. N., Wilson, P. D., & Staruschenko, A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.10.004 · Cited by 66 · cited 1×
“These pathophysiological changes are mainly due to the overactivation of EGFR, cAMP, and mTOR pathway, leading to great interest in research regarding the inhibition of this signaling pathway in the treatment of this disease [96, 97].”
BackgroundRole of mTOR Inhibitors in Kidney Disease
Kajiwara, M., & Masuda, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060975 · Cited by 66 · cited 3×
“, sorafenib, sunitinib, and axitinib), (iii) anti-VEGF monoclonal antibody, and (iv) mTORC1 inhibitors, taking into account their potential to simultaneously inhibit both tumor cell proliferation and angiogenesis [122, 127].”
BackgroundResultTorras, J., Herrero-Fresneda, I., Gulias, O., Flaquer, M., Vidal, A., Cruzado, J. M., Lloberas, N., Franquesa, M. {. D. }., & Grinyo, J. M. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp367 · Cited by 65
Increased Tubular Proliferation as an Adaptive Response to Glomerular Albuminuria
Guo, J.-K., Marlier, A., Shi, H., Shan, A., Ardito, T. A., Du, Z.-P., Kashgarian, M., Krause, D. S., Biemesderfer, D., & Cantley, L. G. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011040396 · Cited by 65 · cited 1×
“, metabolic, immunological, and toxic) acquiring a hypertrophic phenotype [55, 56].”
BackgroundHassan, B., Akcakanat, A., Sangai, T., Evans, K. W., Adkins, F., Eterovic, A. K., Zhao, H., Chen, K., Chen, H., Do, K.-A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2337 · Cited by 61 · cited 1×
“Remarkably, mTOR kinase inhibitors (TOR-KIs) were effective antiproliferators in cell models displaying insensitivity to the first-generation of mTOR inhibitors [46, 47].”
BackgroundmTOR controls kidney epithelia in health and disease
Grahammer, F., Wanner, N., & Huber, T. B. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft491 · Cited by 61 · cited 1×
“Whereas, the precise roles played by mTORC1 and mTORC2 complexes in the different types of renal cells is not fully unveiled during development nor in the adulthood, it is suggested that mTOR signaling pathways impact glomerular and tubulointerstitial renal physiological processes [54].”
BackgroundCordido, A., Cerecedo, L. B., & García-González, M. Á. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00279 · Cited by 60 · cited 1×
“This pathologic entity comprises several Mendelian diseases including autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and atypical PKD forms [86, 87].”
BackgroundStallone, G., Infante, B., Grandaliano, G., Bristogiannis, C., Macarini, L., Mezzopane, D., Bruno, F., Montemurno, E., Schirinzi, A., Sabbatini, M., et al. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs264 · Cited by 59
Gattone, V. H., Sinders, R. M., Hornberger, T. A., & Robling, A. G. (2009) · Kidney International · doi:10.1038/ki.2009.147 · Cited by 58 · cited 1×
“Nevertheless, a lack of efficacy was observed in the PCK rat model of ARPKD, Han:SPRD female rats, and early-stage nephronophthisis pcy mice [97, 101, 105].”
BackgroundLu, M., Wang, J., Ives, H. E., & Pearce, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.257592 · Cited by 58 · cited 1×
“Concurrently, in vitro data have been suggested on the involvement of mTORC2 in renal tubular Na balance regulation [66].”
BackgroundTherapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma
Husseinzadeh, H. D., & Garcia, J. A. (2011) · Current Clinical Pharmacology · doi:10.2174/157488411797189433 · Cited by 56
Lebranchu, Y., Snanoudj, R., Toupance, O., Weestel, P.-F., de Ligny, B. H., Büchler, M., Rérolle, J. P., Thierry, A., Moulin, B., Subra, J., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04036.x · Cited by 55 · cited 1×
“This disadvantage was not resolved by increasing the dose, a strategy which was associated with more adverse effects [73].”
BackgroundElfiky, A. A., Aziz, S. A., Conrad, P. J., Siddiqui, S., Hackl, W., Maira, S.-M., Robert, C. L., & Kluger, H. M. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-133 · Cited by 54 · cited 1×
“Recent research efforts have been placed in other classes of mTOR inhibitors [128, 133].”
BackgroundERK1/2-dependent activation of mTOR/mTORC1/p70S6K regulates thrombin-induced RPE cell proliferation
Parrales, A., López, E., Lee-Rivera, I., & López-Colomé, A. M. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.12.023 · Cited by 54 · cited 1×
“, serum- and glucocorticoidinduced protein kinase 1, SGK1; protein kinases C, PKC) has been linked with mTORC2 activation, with important consequences on cell survival, cytoskeleton organization, and cycle progression [14, 20, 21].”
BackgroundPalavra, F., Robalo, C., & Reis, F. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9820181 · Cited by 53 · cited 2×
“Nevertheless, this molecule also exhibits immunosuppressant, cytostatic, antiangiogenic, and antiproliferative properties, expanding the clinical applications to transplantation and oncology fields [10].”
BackgroundSelf-citationBooij, T. H., Bange, H., Leonhard, W. N., Yan, K., Fokkelman, M., Kunnen, S. J., Dauwerse, J. G., Qin, Y., van de Water, B., van Westen, G. J. P., et al. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217716056 · Cited by 52
Long-Term Treatment of Sirolimus but Not Cyclosporine Ameliorates Diabetic Nephropathy in the Rat
Wittmann, S., Daniel, C., Stief, A., Vogelbacher, R., Amann, K., & Hugo, C. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a192bd · Cited by 51 · cited 1×
“Finally, mTOR seems also to participate in the epithelial-to-mesenchymal transition, a mechanism that is inhibited by rapamycin [142, 152].”
BackgroundKim, T., Choi, S. J., Lee, Y. H., Song, G. G., & Ji, J. D. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.08.022 · Cited by 50 · cited 1×
“rheumatoid arthritis, atherosclerosis and a wide spectrum of neurologic disorders where aberrant mTOR pathway activity is consistently observed [22, 27, 28, 32].”
BackgroundFuhrmann, A., Lopes, P., Sereno, J., Pedro, J., Espinoza, D., Pereira, M. J., Reis, F., Eriksson, J. W., & Carvalho, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.020 · Cited by 49
Self-citationInhibiting 4EBP1 in Glioblastoma
Fan, Q. W., Nicolaides, T. P., & Weiss, W. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0042 · Cited by 48 · cited 1×
“Despite its size, Rapalink-1 can cross blood-brain barrier and has shown increased efficacy in a glioblastoma cell model as well as in a genetically engineered in vivo model of brain cancer, when compared with earlier mTOR inhibitors [52].”
Reis, F., Parada, B., Teixeira‐Lemos, E., Garrido, P., Dias, A., Piloto, N., Baptista, S., Sereno, J., Eufrásio, P., Costa, E. M., et al. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.02.005 · Cited by 47
Self-citationDiscovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors
Han, F., Lin, S., Liu, P., Liu, X., Tao, J., Deng, X., Yi, C., & Xu, H. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5005014 · Cited by 43 · cited 2×
“These new agents are a class of catalytic ATP competitive inhibitors that exert their effects by binding indiscriminately to the ATP-binding site on both mTORC1/2 and PI3K catalytic domains (see Figure 1), which are two crucial signaling hubs [26, 40].”
BackgroundAn mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease
Ravichandran, K., Zafar, I., Ozkok, A., & Edelstein, C. L. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu296 · Cited by 42 · cited 2×
“In this regard, the mTOR kinase inhibitors appear to have a low side effect profile besides their ability to inhibit both mTORC1 and 2 complexes [109, 121].”
BackgroundLi, A., Fan, S., Xu, Y., Meng, J., Shen, X., Mao, J., Zhang, L., Zhang, X., Moeckel, G., Wu, D., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13091 · Cited by 42
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Bolignano, D., Palmer, S. C., Ruospo, M., Zoccali, C., Craig, J. C., & Strippoli, G. F. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010294.pub2 · Cited by 39 · cited 1×
“Overall, these clinical results were largely disappointing, taking into account the promising effects of mTOR inhibition in PKD animal models and retrospective studies of kidney transplant recipients undergoing immunosuppression with mTOR inhibitors who displayed reduced liver cystic phenotype [115, 116].”
ResultReduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients
Russ, G. R., Campbell, S. B., Chadban, S., Eris, J., O’Connell, P. R., Pussell, B. A., & Walker, R. G. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00210-0 · Cited by 38 · cited 1×
“The combination of sirolimus with a reduced exposure to tacrolimus also showed a low incidence of acute rejection and a trend towards better graft function [82].”
BackgroundMammalian target of rapamycin signaling in the podocyte
Inoki, K., & Huber, T. B. (2012) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e3283520f38 · Cited by 38 · cited 1×
“Noteworthy, this compensatory mechanism related to size control seems to be mTOR-mediated [57, 58].”
BackgroundAutosomal dominant polycystic kidney disease in a family with mosaicism and hypomorphic allele
Reiterová, J., Štekrová, J., Merta, M., Kotlas, J., Elišáková, V., Lněnička, P., Korabečná, M., Kohoutová, M., & Tesař, V. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-59 · Cited by 35 · cited 1×
“ADPKD is the most common life-threatening hereditary renal disease, with an incidence of 1 : 400 to 1 : 1000 individuals [88].”
BackgroundGrahammer, F., Wanner, N., & Huber, T. B. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.04.009 · Cited by 34
Recent developments in small molecule therapies for renal cell carcinoma
Song, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.007 · Cited by 31 · cited 1×
“Yet, other driver mutations are also involved in the ccRCC development, including those responsible for the constitutive increase in mTOR activation [123, 124].”
BackgroundPascual, J., Srinivas, T. R., Chadban, S. J., Citterio, F., Oppenheimer, F., Junior, H. T. S., Henry, M. L., Legendre, C. M., Watarai, Y., Sommerer, C., et al. (2014) · Open Access Journal of Clinical Trials · doi:10.2147/oajct.s63058 · Cited by 28 · cited 1×
“The challenge of combining efficacy and safety while preventing episodes of acute rejection, and maintaining good long-term graft function, is well present in the ongoing TRANSFORM trial (Advancing renal TRANSplant efficacy Outcomes with an eveRoliMus-based regimen) (NCT01950819), whose final conclusions are expected…”
BackgroundIchikawa, A., Nakahara, T., Kurauchi, Y., Mori, A., Sakamoto, K., & Ishii, K. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23358 · Cited by 26 · cited 1×
“Examples of mTORC1 downstream effectors are the lipin 1/SREBP (sterol regulatory element-binding proteins), the p70S6 kinases (S6K1 and S6K2), and the EIF4EBP1 (eukaryotic translation initiation factor 4E-binding protein 1) [16, 17].”
BackgroundBian, Y., Xu, J., Zhao, W., Zhang, Z., Tu, L., Cao, H., & Zhang, Z. (2017) · Europe PMC (PubMed Central) · Cited by 25
Lopes, P. C. M. M., Fuhrmann, A., Sereno, J., Espinoza, D., Pereira, M. J., Eriksson, J. W., Reis, F., & Carvalho, E. (2014) · Metabolism · doi:10.1016/j.metabol.2014.02.004 · Cited by 24
Self-citationSereno, J., Vala, H., Nunes, S., Rocha‐Pereira, P., Carvalho, E., Alves, R., Teixeira, F. J., & Reis, F. (2015) · PubMed · Cited by 23
Self-citationHe, Q., Lin, C.-Y. A., Ji, S., & Chen, J. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318256754f · Cited by 22
Haller, M., Amatschek, S., Wilflingseder, J., Kainz, A., Bielesz, B. O., Pavik, I., Serra, A. L., Mohebbi, N., Biber, J., Wagner, C. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039229 · Cited by 19 · cited 1×
“Apart from proteinuria, subjects under sirolimus therapy may develop hypophosphatemia and hypokalemia; since phosphaturia is a reliable outcome, and considering that in vivo mTORC1 inhibition does not seem to affect the apical phosphate reabsorption machinery [65], it could be conjectured whether mTORC1 could affect t…”
BackgroundA new generation of mTORC1 inhibitor attenuates alcohol intake and reward in mice
Morisot, N., Novotny, C. J., Shokat, K. M., & Ron, D. (2017) · Addiction Biology · doi:10.1111/adb.12528 · Cited by 19 · cited 1×
“Moreover, this compound did not display significant toxicity events when given intraperitoneally in mice and was also recently suggested as a possible new alternative to treat and prevent the development of alcohol use disorder (AUD) [53].”
BackgroundMammalian target of rapamycin (mTOR) inhibitors in solid tumours
(2016) · Clinical pharmacist · doi:10.1211/cp.2016.20200813 · Cited by 19
Lopes, P. C. M. M., Fuhrmann, A., de Carvalho, F. J. N., Sereno, J., Santos, M. R., Pereira, M. J., Eriksson, J. W., Reis, F., & Carvalho, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.06.014 · Cited by 16
Self-citationLopes, P., Fuhrmann, A., Sereno, J., Pereira, M. J., Nunes, P. M., Pedro, J., Melão, A., Reis, F., & Carvalho, E. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2013.02.009 · Cited by 15
Self-citationTargeting the PI3K/AKT/mTOR Pathway in Cancer Cells
Guimarães, I. D. S., Tessarollo, N. G., Junior, P. C. M. L., dos Santos, D. Z., Zampier, R. C., de Oliveira, L. F. R. L., Siqueira, K. V., Silva, I. V., & Rangel, L. B. A. (2015) · InTech eBooks · doi:10.5772/61676 · Cited by 15 · cited 5×
“rheumatoid arthritis, atherosclerosis and a wide spectrum of neurologic disorders where aberrant mTOR pathway activity is consistently observed [22, 27, 28, 32].”
BackgroundInfluentialPalavra, F., Ambrósio, A. F., & Reis, F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00002-5 · Cited by 15
Self-citationThe human gene encoding FKBP-rapamycin associated protein (FRAP) maps to chromosomal band 1p36.2
Lench, N., Macadam, R., & Markham, A. F. (1997) · Human Genetics · doi:10.1007/s004390050404 · Cited by 14 · cited 1×
“mTOR is a member of the phosphatidylinositol 3-kinaserelated kinase (PIKK) family, which is one of the key players of cellular metabolism that is coupled with nutrient availability, energy, and homeostasis [5, 6].”
BackgroundMycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease
ZHANG, T., Wang, L., Xiong, X., Mao, Z., Wang, L., & Mei, C. (2009) · Biological Research · doi:10.4067/s0716-97602009000400005 · Cited by 13
Xiong, Z., Zang, Y., Zhong, S., Zou, L., Wu, Y., Liu, S., Fang, Z., Shen, Z., Ding, Q., & Chen, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15620 · Cited by 11 · cited 1×
“Moreover, this molecule was also able to elicit HIF-1α/2α downregulation in RCC cells with putative antiangiogenic effects, strengthening the value of XL388 for future clinic evaluation [137].”
BackgroundSereno, J., Nunes, S., Rodrigues‐Santos, P., Vala, H., Rocha‐Pereira, P., Fernandes, J. C., Santos‐Silva, A., Teixeira, F. J., & Reis, F. (2014) · BioMed Research International · doi:10.1155/2014/576929 · Cited by 10
Self-citationSereno, J., Parada, B., Rodrigues‐Santos, P., Lopes, P. C., Carvalho, E., Vala, H., Teixeira‐Lemos, E., Alves, R., Figueiredo, A., Mota, A., et al. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2013.02.085 · Cited by 9
Self-citationCardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model.
Sereno, J., Romão, A. M., Parada, B., Lopes, P. C. M. M., Carvalho, E., Teixeira, F. J., & Reis, F. (2012) · PubMed Central · doi:10.4103/0976-500x.95513 · Cited by 7
Self-citationmTOR in Diabetic Nephropathy and Retinopathy
Fernandes, R., & Reis, F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00001-3 · Cited by 4 · cited 3×
“mTOR pathway signaling abnormalities seem to be present in all the key steps of DN progression, including (i) podocyte damage and loss, an early event in DN that further causes glomerulosclerosis; (ii) overactivation of mesangial cells that promotes increased ECM synthesis and decreased degradation of damaged podocyte…”
BackgroundInfluentialSelf-citationVan Caenegem, O., De Pauw, M., Vorlat, A., Roussoulières, A., Ancion, A., Verstreken, S., Van Cleemput, J., & 18th Congress of the European Society of Organ Transplantation (2017) · Transplant International · doi:10.1111/tri.13072 · Cited by 2
Cited by
Autophagy in kidney homeostasis and disease
Tang, C., Livingston, M. J., Liu, Z., & Dong, Z. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0309-2 · Cited by 496
The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities
Rašková, M., Lacina, L., Kejík, Z., Venhauerová, A., Skaličková, M., Kolář, M., Jakubek, M., Rosel, D., Smetana, K., & Brábek, J. (2022) · Cells · doi:10.3390/cells11223698 · Cited by 226
Recent advances and limitations of mTOR inhibitors in the treatment of cancer
Ali, E. S., Mitra, K., Akter, S., Ramproshad, S., Mondal, B., Khan, I. N., Islam, M. T., Sharifi-Rad, J., Calina, D., & Cho, W. C. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02706-8 · Cited by 207
“Adverse reactions such as nephrotoxicity, and increased risk of malignancy or infections require careful monitoring of treatment [108].”
BackgroundmTOR signalling pathway - A root cause for idiopathic autism?
Ganesan, H., Balasubramanian, V., Iyer, M., Venugopal, A., Subramaniam, M. D., Cho, S.-G., & Vellingiri, B. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.7.137 · Cited by 73
“cardiovascular disease (45), renal diseases (46), pulmonary fibrosis (47), and diabetes mellitus (48).”
BackgroundModulation of mTOR Signaling in Cardiovascular Disease to Target Acute and Chronic Inflammation
Kaldirim, M., Lang, A., Pfeiler, S., Fiegenbaum, P., Kelm, M., Bönner, F., & Gerdes, N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.907348 · Cited by 73
“Meanwhile, mTOR inhibitors have made significant progress in their utilization to modulate the immune response in a variety of disease disorders (6).”
Background
Metadata
- Authors
- Viana, S. D., Reis, F., & Alves, R.
- Affiliations
- Universidade Politécnica de Coimbra (PT)
- Centro de Inovação em Biomedicina e Biotecnologia (PT)
- Unidade Local de Saúde de Coimbra (PT)
- Corresponding author
- Reis, Flávio
- Alves, Rui
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 2018
- Issue
- 1
- Pages
- 3693625-3693625
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- PMC
- PMC6231362
- OpenAlex
- W2899387091
- Cited by
- 48
- References
- 154
- Citations by year
- 2025: 6 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 8 · 2020: 10 · 2019: 6
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Oxidative Medicine and Cellular Longevity (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- Funders
- Fundação para a Ciência e a Tecnologia
- European Regional Development Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- mTOR inhibitors, mTOR signaling, mTORC1, mTORC2, rapamycin, everolimus, temsirolimus, kidney disease, kidney transplantation, polycystic kidney disease, renal carcinoma, diabetic nephropathy, immunosuppression, age-related diseases
- MeSH terms
- Animals, Humans, Kidney Diseases, Protein Kinase Inhibitors, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.